- ISIN
- US98937L1052
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 13, 2024
Highlights
- Market Cap
- $1.16B
- Enterprise Value
- $852.55M
- EPS (TTM)
- -$9.14
- Total Revenue (TTM)
- $10.00M
- Gross Profit (TTM)
- -$48.04M
- EBITDA (TTM)
- -$255.29M
- Year Range
- $8.91 - $44.60
- Target Price
- $33.50
- ROA (TTM)
- -56.86%
- ROE (TTM)
- -126.60%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ZBIO Performance Chart
Zenas BioPharma, Inc (ZBIO) is down 42.7% since the beginning of the year. At $21 per share, ZBIO is trading 53.4% below its 52-week high of $45.
Loading charts...
Returns By Period
Zenas BioPharma, Inc (ZBIO) has returned -42.72% so far this year and 126.33% over the past 12 months.
Zenas BioPharma, Inc
- 1D
- 5.16%
- 1M
- 9.65%
- YTD
- -42.72%
- 6M
- -50.86%
- 1Y
- 126.33%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ZBIO Monthly Returns History
Based on dividend-adjusted daily data since Sep 13, 2024, ZBIO's average daily return is +0.27%, while the average monthly return is +4.92%. At this rate, an investment would double in approximately 1.2 years.
Historically, 50% of months were positive and 50% were negative. The best month was Jul 2025 with a return of +62.1%, while the worst month was Jan 2026 at -49.4%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, ZBIO closed higher 51% of trading days. The best single day was Oct 27, 2025 with a return of +33.1%, while the worst single day was Jan 5, 2026 at -51.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -49.41% | 43.44% | -25.81% | -1.18% | -4.76% | 13.04% | -42.72% | ||||||
| 2025 | -2.08% | -12.59% | 12.70% | 46.58% | -17.79% | 1.79% | 62.13% | 1.85% | 38.75% | 40.77% | 24.26% | -6.49% | 343.35% |
| 2024 | -7.79% | 25.50% | -45.80% | -28.84% | -55.37% |
Benchmark Metrics
Zenas BioPharma, Inc has an annualized alpha of 57.60%, beta of 1.31, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since September 13, 2024.
- This stock tended to rise when S&P 500 Index fell (downside capture of -283.90%), but participation in market rallies was also limited (-36.38%) - a profile typical of counter-cyclical assets.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 57.60%
- Beta
- 1.31
- R²
- 0.04
- Upside Capture
- -36.38%
- Downside Capture
- -283.90%
Return for Risk
Risk / Return Rank
ZBIO ranks 75 for risk / return — better than 75% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Zenas BioPharma, Inc (ZBIO) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ZBIO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.90 | ||
| Sortino ratioReturn per unit of downside risk | -0.80 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.37 | -0.07 |
| Calmar ratioReturn relative to maximum drawdown | 1.96 | 2.78 | -0.82 |
| Martin ratioReturn relative to average drawdown | 3.56 | 12.44 | -8.88 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Zenas BioPharma, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Zenas BioPharma, Inc was 74.96%, occurring on Jan 28, 2025. Recovery took 175 trading sessions.
The current Zenas BioPharma, Inc drawdown is 51.82%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -74.96%Jan 2025 | 3mo 7d | 8mo 13d | 11mo 20dOct 2024 - Oct 2025 |
2026 bear market2026 | -64.79%Jan 2026 | 11d | — | 5mo 29dDec 2025 - now |
2025 correction2025 | -19.71%Dec 2025 | 0s | 7d | 7dDec 2025 - Dec 2025 |
2025 correction2025 | -14.88%Dec 2025 | 4d | 10d | 14dNov 2025 - Dec 2025 |
2025 correction2025 | -13.92%Oct 2025 | 14d | 3d | 17dOct 2025 - Oct 2025 |
Drawdown Indicators
| ZBIO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.96% | -56.78% | -18.18% |
Max Drawdown (1Y)Largest decline over 1 year | -64.79% | -9.10% | -55.69% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -51.82% | -1.80% | -50.02% |
Average DrawdownAverage peak-to-trough decline | -42.89% | -10.71% | -32.18% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.67% | 2.03% | +33.64% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Zenas BioPharma, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Zenas BioPharma, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ZBIO relative to other companies in the Biotechnology industry. Currently, ZBIO has a P/S ratio of 96.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ZBIO in comparison with other companies in the Biotechnology industry. Currently, ZBIO has a P/B value of 3.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ZBIO
Add Zenas BioPharma, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ZBIO